Martin Mattingly Net Worth

Martin Mattingly biography

Dr. Martin A. Mattingly Ph.D. serves as Independent Director of the Company. He has served as a director since June 2010. Since December 2014 has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky. The determination was made that Dr. Mattingly should serve on the Board of Directors as a result of his executive leadership experience in late-stage clinical development, public company expertise, and commercialization and business development experience with pharmaceuticals and biologics.

How old is Martin Mattingly?

Martin Mattingly is 63, he's been the Independent Director of Achieve Life Sciences since 2010. There are 6 older and 9 younger executives at Achieve Life Sciences. The oldest executive at Achieve Life Sciences Inc. is Donald Joseph, 66, who is the Independent Director.

What's Martin Mattingly's mailing address?

Martin's mailing address filed with the SEC is C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO, CA, 92122.

Insiders trading at Achieve Life Sciences

Over the last 7 years, insiders at Achieve Life Sciences have traded over $972,224 worth of Achieve Life Sciences stock and bought 70,500 units worth $224,475 . The most active insiders traders include Capital, Llc Armistice Capi..., Vaughn B Himes, eJay M Moyes. On average, Achieve Life Sciences executives and independent directors trade stock every 65 days with the average trade being worth of $63,759. The most recent stock trade was executed by Jerry Wan on 19 April 2024, trading 5,625 units of ACHV stock currently worth $24,075.

What does Achieve Life Sciences do?

achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.

Achieve Life Sciences executives and stock owners

Achieve Life Sciences executives and other stock owners filed with the SEC include:

• Richard Stewart,
  Executive Chairman of the Board
• John A. Bencich M.B.A.,
  CEO & Director
• Dr. Richard A. B. Stewart,
  Exec. Chairman
• John A. Bencich,
  CEO & Director
• Anthony Clarke,
  Chief Science Officer
• Cindy Jacobs,
  President
• Dr. Cindy Jacobs M.D., Ph.D.,
  Pres, Chief Medical Officer & Director
• John Bencich,
  Chief Executive Officer, Principal Executive Officer, Director
• Dr. Anthony Clark,
  Chief Scientific Officer
• Scott Cormack,
  Director
• Jason Wong,
  IR Contact Officer
• H. Stewart Parker,
  Independent Director
• Jay Moyes,
  Independent Director
• Martin Mattingly,
  Independent Director
• Donald Joseph,
  Independent Director
• Jerry Wan,
  Principal Accounting Officer
• Dr. Anthony Clarke,
  Chief Scientific Officer
• Jaime Xinos,
  Exec. VP of Commercial
• Jerry Wan,
  Principal Accounting Officer
• Vaughn B Himes,
  Director
• Financial Groupsvb Innovati...,
  
• Capital, Llc Armistice Capi...,
  
• Bridget A Martell,
  Director
• Thomas Braxton King,
  Director
• Stuart Duty,
  Director
• Thomas Sellig,
  Director